Compare · APUS vs NVO
APUS vs NVO
Side-by-side comparison of Apimeds Pharmaceuticals US Inc. (APUS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APUS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 25643.9x APUS ($6.8M).
- APUS has been more active in the news (7 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for APUS).
- Company
- Apimeds Pharmaceuticals US Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $6.8M
- $173.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2025
- News (4w)
- 7
- 3
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest APUS
- NILA Token to Begin Trading on Pionex, Opening Access to Eligible Users Worldwide
- SEC Form 8-K filed by Apimeds Pharmaceuticals US Inc.
- MindWave Innovations Signs 3 Client Network Agreements in 10 Days, Extending MindChain into Climate Finance, Sports Media and Insurance; Apimeds Pharmaceuticals US Provides Required NYSE American Disclosure
- MindWave Innovations Signs Agreement with US-Based BlockAssure to Build and Operate AssureChain, an End-to-End Insurance and Reinsurance Network
- Apimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Apimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- MindWave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate FlashChain for New York-Based Flash Sports & Media
- MindWave Innovations Signs Agreement to Build and Operate AQUAEChain, a Platform for Insured ALCI Credits
- Apimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- IBN Initiates Coverage of Apimeds Pharmaceuticals US, Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank